Epithelial ovarian cancer: Review article.
Sambasivan S.
Cancer Treat Res Commun. 2022;33:100629. doi: 10.1016/j.ctarc.2022.100629. Epub 2022 Sep 8.
Imaging strategy in recurrent ovarian cancer: a practical review.
Manganaro L, Gigli S, Antonelli A, Saldari M, Tomao F, Marchetti C, Anastasi E, Laghi A.
Abdom Radiol (NY). 2019 Mar;44(3):1091-1102. doi: 10.1007/s00261-018-1677-y.
Surgery in recurrent ovarian cancer.
Sehouli J, Grabowski JP.
Cancer. 2019 Dec 15;125 Suppl 24:4598-4601. doi: 10.1002/cncr.32511.
Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?
Glajzer J, Grabowski JP, Sehouli J, Pfisterer J.
Curr Treat Options Oncol. 2020 Apr 30;21(6):49. doi: 10.1007/s11864-020-00747-7.
Recurrent Ovarian Cancer - Sculpting a Promising Future with Surgery.
Gardner GJ, Chi DS.
N Engl J Med. 2021 Dec 2;385(23):2187-2188. doi: 10.1056/NEJMe2116353.
Treatment for recurrent epithelial ovarian cancer.
Li YT, Liu CH, Wang PH.
Taiwan J Obstet Gynecol. 2021 Sep;60(5):803-804. doi: 10.1016/j.tjog.2021.07.003.
Management and Treatment of Recurrent Epithelial Ovarian Cancer.
Armbruster S, Coleman RL, Rauh-Hain JA.
Hematol Oncol Clin North Am. 2018 Dec;32(6):965-982. doi: 10.1016/j.hoc.2018.07.005.
Platinum or nonplatinum in recurrent ovarian cancer: that is the question.
Poveda A, Marth C.
Future Oncol. 2017 Oct;13(23s):11-16. doi: 10.2217/fon-2017-0317. Epub 2017 Oct 11.
Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis.
Lorusso D, Sabatucci I, Maltese G, Lepori S, Tripodi E, Bogani G, Raspagliesi F.
Tumori. 2019 Aug;105(4):282-287. doi: 10.1177/0300891619839308. Epub 2019 Mar 28.
Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.
Buechel M, Herzog TJ, Westin SN, Coleman RL, Monk BJ, Moore KN.
Ann Oncol. 2019 May 1;30(5):721-732. doi: 10.1093/annonc/mdz104.
